ArticleMetabolic brain disease2025
SOCS2 alleviates traumatic brain injury-induced mitochondrial damage and parthanatos in endothelial cells by inhibiting the JAK2/STAT3 signaling pathway.
Article in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Coptisine suppresses oral squamous cell carcinoma via regulating the JAK2/STAT3 to induce mitochondrial dysfunction in cancer cells and promote macrophage polarization to M1.American journal of cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTraumatic brain injury (TBI) is an important cause of death and disability worldwide. Vascular endothelial cells (ECs) injury has been confirmed to be a risk factor for the development of severe sequelae of TBI, and suppressor of cytokine signaling 2 (SOCS2) regulates the fate of endothelial cells. Therefore, this study aimed to investigate the role of SOCS2 in EC injury after TBI and elucidate its potential molecular mechanisms.
methodsA TBI rat model was induced via controlled cortical impact (CCI), and a TBI cell model was constructed by treating RBE4 cells with oxygen-glucose deprivation (OGD). RT‒qPCR and western blotting were used to detect key gene and protein expression levels; JC-1 staining was applied to measure the mitochondrial membrane potential; a lactate dehydrogenase (LDH) release assay was conducted to assess the cell death rate; flow cytometry was utilized to detect reactive oxygen species (ROS) levels; and a neutral comet assay was performed to evaluate DNA damage. Additionally, hematoxylin‒eosin (H&E) staining, syndecan-1 content measurement, and the Evans blue extravasation test were combined to comprehensively assess brain tissue pathology and blood‒brain barrier integrity.
resultsOur study revealed that in TBI rat brain tissues and OGD-treated RBE4 cells, the expression of the endothelial barrier-related proteins ZO-1 and Occludin decreased, whereas the levels of parthanatos-associated proteins (PARP1, PAR, and nuclear AIF), JAK2/STAT3 signaling pathway activation markers (p-JAK2/JAK2 and p-STAT3/STAT3), and the DNA damage marker γ-H2AX significantly increased. Additionally, both TBI rat brain tissues and OGD-treated RBE4 cells exhibited reduced mitochondrial membrane potential and elevated ROS levels, with OGD-induced RBE4 cells showing substantial DNA damage and cell death. Notably, the expression of SOCS2 was downregulated in both the TBI and OGD models, and SOCS2 overexpression markedly alleviated the aforementioned injuries induced by TBI or OGD, suggesting that SOCS2 might mitigate TBI-related endothelial cell damage by reducing mitochondrial impairment and parthanatos. Mechanistically, SOCS2 attenuated PARP1-mediated mitochondrial damage and parthanatos by promoting PARP1 ubiquitination, triggering its degradation, and inhibiting the activation of the JAK2/STAT3 signaling pathway, ultimately ameliorating TBI-induced endothelial cell injury.
conclusionOur study revealed a novel regulatory role of SOCS2 in EC injury following TBI and elucidated its underlying mechanism. This discovery of the previously unknown role of the SOCS2-PARP1-JAK2/STAT3 regulatory axis in the TBI-related damage to ECs will provide new ideas for the development of neuroprotective strategies targeting SOCS2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.